Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Fevara plc is an international, pure-play specialist agriculture manufacturer and provider of research-proven, value-added livestock supplements. Headquartered in Carlisle, Cumbria, United Kingdom, and founded in 1831, the company develops, manufactures, and markets nutritional products including feed licks, blocks, bagged minerals, and boluses for cattle, sheep, horses, and goats in extensive grazing systems. Its globally recognized brands encompass Crystalyx®, Horslyx®, SmartLic®, HorsLic®, Tracesure®, Scotmin Nutrition®, and others, designed to boost farmer profitability, enhance resource efficiency, and promote sustainable agriculture. Fevara operates seven manufacturing sites across the UK, Germany, and the US, serving customers in more than 20 countries through an expansive distribution network. Formerly known as Carr's Group plc until September 2025, it focuses on strategic priorities like improving operating margins, delivering profitable growth, and expanding into new markets, employing around 200 people. In the financial markets, Fevara plc represents a niche player in the consumer staples sector, particularly packaged foods for animal nutrition.
£1.37
+£0.02 (+1.87%)
EOD Jul 3, 2026
Operating margin is thin at 1.31%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 4.1%, steady but not accelerating.
Even for strong businesses, today's 6x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
6.0x earnings, 18.2x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£79M
▲ +4.1% YoY
Net Income (TTM)
£20M
▲ +448.5% YoY
Op. Margin
1.31%
▲ +12.1pp YoY
ROIC
1.43%
▲ +6.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
£6M
▲ +3.4% YoY
Op. Cash Flow (TTM)
£8M
▲ +3.0% YoY
Net Debt
-£2M
Net Cash Position
Cash & Equiv.
£8M
3Y CAGR: -14.1%
Continue Research
At a P/E of 6.0 and a price-to-free-cash-flow of 18.2, Fevara (FVA.XLON) trades above a two-stage DCF intrinsic value of about £1.32 per share, so at £1.37 the stock looks overvalued (3.6% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Fevara scores 51/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 3.2%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about £1.32 per share for FVA.XLON, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around £0.99. At today's £1.37, that puts the stock about 3.6% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Fevara scores 51 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 1.3% operating margin and a 1.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Fevara pays a regular dividend of about £0.04 per share per year (typically in quarterly installments), a yield of roughly 3.2% at the current price. That is a payout ratio of about 19.2% of earnings, so the dividend is amply covered by earnings. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For FVA.XLON's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. FVA.XLON currently trades above its estimated intrinsic value and scores 51/100 on quality (mixed). It also yields about 3.2%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.